2026-08-29T19:28:22Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/142342024-09-27T20:44:05Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19609

00925njm 22002777a 4500 dc García de la Sota, Patricia author Lorente, Elena author Notario, Laura author Mir-Gerrero, Carmen author Zaragoza, Oscar author Lopez, Daniel author 2021-09-07 Human respiratory syncytial virus (HRSV) is the most common cause of severe respiratory infections in infants and young children, often leading to hospitalization. In addition, this virus poses a serious health risk in immunocompromised individuals and the elderly. HRSV is also a major nosocomial hazard in healthcare service units for patients of all ages. Therefore, the development of antiviral treatments against HRSV is a global health priority. In this study, mitoxantrone, a synthetic anthraquinone with previously reported in vitro antiprotozoal and antiviral activities, inhibits HRSV replication in vitro, but not in vivo in a mice model. These results have implications for preclinical studies of some drug candidates. Biomedicines. 2021;9(9):1176. 10.3390/biomedicines9091176 2227-9059 Biomedicines 34572362 http://hdl.handle.net/20.500.12105/14234 HRSV Antivirals Bioluminescence Drugs Mitoxantrone Shows In Vitro, but Not In Vivo Antiviral Activity against Human Respiratory Syncytial Virus